Dendrogenix Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Private

  • Employees
  • 12

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $15.8M

  • Investors
  • 2

Dendrogenix General Information

Description

Operator of a biotech company intended to develop molecules, dendrogenins, to address good unmet medical needs in hearing loss and neurology. The company's molecules address the important medical needs in the field of neurodegenerative diseases, enabling medical practitioners to have a treatment alternative for hearing loss and cancer.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Avenue de l Hopital, 11
  • SPS Batiment 34, 3rd Floor
  • 4000 Liege
  • Belgium
+32 04
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Corporate Office
  • Avenue de l Hopital, 11
  • SPS Batiment 34, 3rd Floor
  • 4000 Liege
  • Belgium
+32 04

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Dendrogenix Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC 20-Dec-2023 $15.8M Completed Clinical Trials - Phase 1
4. Accelerator/Incubator 03-Jun-2019 Completed Product Development
3. Early Stage VC 18-Dec-2018 Completed Product Development
2. Grant 10-Nov-2018 $2.8M $1.94M Completed Product Development
1. Early Stage VC 10-Nov-2018 $1.94M $1.94M Completed Product Development
To view Dendrogenix’s complete valuation and funding history, request access »

Dendrogenix Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Class B
Class A
Class B
Class A
Ordinary 1,028,824 $4.23 $4.23 1x $4.23 7.94%
Ordinary 144,679 $3.38 $3.38 1x $3.38 2.23%
To view Dendrogenix’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Dendrogenix Patents

Dendrogenix Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2023291645-A1 Compounds derived from sterols for the treatment of a disease associated with a mitochondrial deficit Pending 14-Jun-2022
EP-4539852-A1 Compounds derived from sterols for the treatment of a disease associated with a mitochondrial deficit Active 14-Jun-2022
US-20260183311-A1 Compounds derived from sterols for the treatment of a disease associated with a mitochondrial deficit Pending 14-Jun-2022
WO-2023242281-A1 Compounds derived from sterols for the treatment of a disease associated with a mitochondrial deficit Inactive 14-Jun-2022
EP-4539852-B1 Sterol derivatives for treating disorders linked to a mitochondrial deficit Active 14-Jun-2022 C07J41/0005
To view Dendrogenix’s complete patent history, request access »

Dendrogenix Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Dendrogenix Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds
Noshaq Venture Capital Minority
Wallonie Entreprendre Growth/Expansion Minority
To view Dendrogenix’s complete investors history, request access »

Dendrogenix FAQs

  • When was Dendrogenix founded?

    Dendrogenix was founded in 2018.

  • Where is Dendrogenix headquartered?

    Dendrogenix is headquartered in Liege, Belgium.

  • What is the size of Dendrogenix?

    Dendrogenix has 12 total employees.

  • What industry is Dendrogenix in?

    Dendrogenix’s primary industry is Drug Discovery.

  • Is Dendrogenix a private or public company?

    Dendrogenix is a Private company.

  • What is the current valuation of Dendrogenix?

    The current valuation of Dendrogenix is .

  • What is Dendrogenix’s current revenue?

    The current revenue for Dendrogenix is .

  • How much funding has Dendrogenix raised over time?

    Dendrogenix has raised $20.5M.

  • Who are Dendrogenix’s investors?

    Noshaq and Wallonie Entreprendre have invested in Dendrogenix.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process